NASDAQ:ATRS - Antares Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.66 -0.03 (-1.12 %)
(As of 06/22/2018 03:12 PM ET)
Previous Close$2.73
Today's Range$2.64 - $2.73
52-Week Range$1.58 - $4.09
Volume16,979 shs
Average Volume852,778 shs
Market Capitalization$442.25 million
P/E Ratio-24.27
Dividend YieldN/A
Beta0.21
Antares Pharma logoAntares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Debt-to-Equity Ratio0.88
Current Ratio2.94
Quick Ratio2.39

Price-To-Earnings

Trailing P/E Ratio-24.27
Forward P/E Ratio-33.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.51 million
Price / Sales7.65
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book12.67

Profitability

EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-32.96%
Return on Equity-52.74%
Return on Assets-23.67%

Miscellaneous

Employees111
Outstanding Shares156,830,000

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) issued its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.01. The specialty pharmaceutical company had revenue of $12.70 million for the quarter, compared to analysts' expectations of $12.85 million. Antares Pharma had a negative net margin of 32.96% and a negative return on equity of 52.74%. View Antares Pharma's Earnings History.

What price target have analysts set for ATRS?

3 equities research analysts have issued 12 month price objectives for Antares Pharma's shares. Their forecasts range from $3.00 to $5.00. On average, they expect Antares Pharma's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, Chief Exec. Officer, Pres and Director (Age 52)
  • Mr. Fred M. Powell CPA, Exec. VP & CFO (Age 57)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. and Corp. Controller (Age 55)
  • Mr. Peter J. Graham Esq., Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
  • Edward Kessig, VP of Sales

Has Antares Pharma been receiving favorable news coverage?

Media coverage about ATRS stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a media sentiment score of 0.17 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.83%), Wells Fargo & Company MN (1.23%), JW Asset Management LLC (1.13%), Russell Investments Group Ltd. (0.57%), Schwab Charles Investment Management Inc. (0.45%) and Guggenheim Capital LLC (0.34%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JW Asset Management LLC, Guggenheim Capital LLC and A.R.T. Advisors LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Which major investors are buying Antares Pharma stock?

ATRS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Wells Fargo & Company MN, Schwab Charles Investment Management Inc. and MetLife Investment Advisors LLC. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.67.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $442.25 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (ATRS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  370
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.